Clinical status and optimal use of rituximab for B-cell lymphomas

被引:0
作者
McLaughlin, P
White, CA
Grillo-López, AJ
Maloney, DG
机构
[1] Univ Texas, MD Anderson Cancer Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Univ Washington, Div Oncol, Seattle, WA 98195 USA
来源
ONCOLOGY-NEW YORK | 1998年 / 12卷 / 12期
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rituximab (IDEC-C2B8 [Rituxan]) is a chimeric anti-CD20 monoclonal antibody (MoAb) that was recently approved by the FDA for the treatment of patients with low-grade or follicular B-cell non-Hodgkin's lymphoma. Its potential efficacy in other B-cell malignancies is currently being explored. This article reviews the mechanisms of action of rituximab, as well as preclinical data and results of the clinical trials that led to ifs approval. Also discussed are the mechanics of administering rituximab on the recommended weekly x 4 outpatient schedule. Finally, the article describes ongoing and planned trials of rituximab irt other dosage schedules, in other B-cell neoplasms, and in conjunction with chemotherapy. As the first MoAb to gain FDA approval for the treatment of a malignancy, rituximab signals the beginning of a promising newer a in cancer therapy.
引用
收藏
页码:1763 / 1769
页数:7
相关论文
共 36 条
  • [1] REDUCED EXPRESSION OF CD20 ANTIGEN AS A CHARACTERISTIC MARKER FOR CHRONIC LYMPHOCYTIC-LEUKEMIA
    ALMASRI, NM
    DUQUE, RE
    ITURRASPE, J
    EVERETT, E
    BRAYLAN, RC
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1992, 40 (04) : 259 - 263
  • [2] ANDERSON KC, 1984, CANCER TREAT REP, V68, P1343
  • [3] EXPRESSION OF HUMAN B CELL-ASSOCIATED ANTIGENS ON LEUKEMIAS AND LYMPHOMAS - A MODEL OF HUMAN B-CELL DIFFERENTIATION
    ANDERSON, KC
    BATES, MP
    SLAUGHENHOUPT, BL
    PINKUS, GS
    SCHLOSSMAN, SF
    NADLER, LM
    [J]. BLOOD, 1984, 63 (06) : 1424 - 1433
  • [4] Coiffier B, 1998, BLOOD, V92, P1927
  • [5] CZUEZMAN MS, 1996, ANN ONCOL S1, V7, P56
  • [6] David TJ, 1997, J ROY SOC MED, V90, P1
  • [7] DAVIS T, 1998, P AN M AM SOC CLIN, V17, pA11
  • [8] Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
    Demidem, A
    Lam, T
    Alas, S
    Hariharan, K
    Hanna, N
    Bonavida, B
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) : 177 - 186
  • [9] ANTIBODIES AS CYTOTOXIC THERAPY
    DILLMAN, RO
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) : 1497 - 1515
  • [10] DILLMAN RO, 1990, ANTIBODY IMMUNOCONJ, V3, P1